PepGen Inc.

NASDAQ:PEPG

Biotechnology

Healthcare
$3.83 +5.29%

+$0.09 today

Market cap
$265.27M
Beta
1.93
P/E (TTM)
-1.6
EPS (TTM)
-$1.12
52W Low $1.01High $7.80

Volume 3.39M

Average 1.37M

PEPG Account Payables

Amounts the company owes suppliers for goods and services received.

PepGen Inc.NASDAQ: PEPG

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables falls 77.0% from a year ago

Account payables stood at $622K at the end of Q1 FY2026, down 77.0% from a year earlier and down 24.3% from the prior quarter. Over 3 fiscal years it compounded at -15.5% a year.

Context

  • Account payables amounted to 0.4% of total assets at the end of Q1 FY2026, down 1.7 pp from a year earlier.
  • Account payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -77.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$622K-24.3% QoQ
Last fiscal yearDec 2025
$822K-53.1% YoY
Year agoMar 2025
$2.7M-77.0% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-77.0%——
1 year-53.1%——
3-year CAGR-15.5%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
822K USD
Year-over-year change
-53.1%
4-year CAGR
-29.0%

Account Payables vs competitors

How PEPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -77.0% is the 6th highest of 8, against a peer median of -21.8%.
  • Account payables amounts to 0.4% of total assets for PEPG, versus a peer median of 1.2%.
PEPG Competitors
Account Payables for PEPG and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CRDFCardiff Oncology, Inc.Mar 2026$5.48M USD+51.0%+60.5%11.1%
FATEFate Therapeutics, Inc.Mar 2026$3.28M USD-21.8%-31.5%1.2%
MOLNMolecular Partners AGMar 2026CHF 1.92M CHF-19.9%-2.0%2.2%
NKTXNkarta, Inc.Mar 2026$1.59M USD+6.4%+5.9%0.4%
ALECAlector, Inc.Mar 2026$1.42M USD-38.8%-26.1%0.6%
PEPGPepGen Inc.Mar 2026$622K USD-77.0%-15.5%0.4%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$435K USD-89.3%+0.6%0.3%
ELTXElicio Therapeutics, Inc.Mar 2026$272K USD-93.3%-37.9%1.2%
Peer median (excluding PEPG) —-21.8%-2.0%1.2%

Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents132.9M181.75M80.77M49.42M60.51M
Short-term Investments0029.63M70.77M87.94M
Net Receivables4.74M58K000
Inventory00000
Other Current Assets04.27M2.27M3.57M2.51M
Total Current Assets139.99M186.08M112.68M123.76M150.96M
Property, Plant & Equipment (Net)636K29.88M28.38M25.15M21.02M
Goodwill00000
Intangible Assets00000
Long-term Investments1.47M0000
Tax Assets00000
Other Non-current Assets1.55M1.47M1.99M1.97M1.92M
Total Non-current Assets3.66M31.36M30.37M27.12M22.94M
Total Assets143.64M217.44M143.05M150.88M173.91M
Account Payables3.24M1.36M1.01M1.75M822K
Short-term Debt00000
Tax Payables02.57M000
Deferred Revenue00000
Other Current Liabilities1.21M2.44M2.37M3.62M4.66M
Total Current Liabilities10.32M18.83M17.53M16.7M12.65M
Long-term Debt000013.82M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities226K0000
Total Non-current Liabilities226K18.98M17.1M15.57M13.82M
Total Liabilities10.55M37.81M34.63M32.26M26.46M
Common Stock02K2K3K7K
Retained Earnings(33.75M)(102.86M)(181.48M)(271.46M)(361.12M)
Accumulated OCI17K(81K)34K23K11K
Other Stockholders Equity00000
Minority Interest00000
Total Equity133.09M179.63M108.42M118.62M147.44M
Total Debt024.53M20.1M18.66M17M
Net Debt(132.9M)(157.22M)(60.67M)(30.76M)(43.51M)

PepGen Inc.

NASDAQ:PEPG

Intrinsic Alpha fair value

Locked

Current Price

$3.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.